Board of Directors
JONATHAN THON, PHD
Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.
JONATHAN THON, PHD
Chief Executive Officer
SVEN KARLSSON
Sven Karlsson is the co-founder and president of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.
SVEN KARLSSON, MBA
President and Chief Business Officer
JOSEPH ITALIANO, PHD
Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of Platelet BioGenesis and chairman of the company’s scientific advisory board.JOSEPH ITALIANO, PHD
PHILIP REILLY, MD, JD
Phil is a venture partner at Third Rock Ventures and has served as chief medical officer of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and chief medical officer of Voyager Therapeutics, chief medical officer of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as chairman and CEO of Interleukin Genetics. He earned his medical; degree at the Yale School of Medicine.PHILIP REILLY, MD, JD
MARK McDADE, MBA
Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.
MARK McDADE, MBA
Executive Chair
RICHARD MURRAY, PHD
Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.RICHARD MURRAY, PHD
Scientific Advisory Board
JOSEPH ITALIANO, PHD
Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of Platelet BioGenesis and chairman of the company’s scientific advisory board.JOSEPH ITALIANO, PHD
ED ENGLEMAN, MD
CEDRIC GHEVAERT, PHD
Cedric Ghevaert, Ph.D., senior lecturer in transfusion medicine at the University of Cambridge and a consulting hematologist for the National Health Service Blood and Transplant division in the UK. Dr. Ghevaert has conducted groundbreaking first-in-man studies of blood cell survival and recovery.CEDRIC GHEVAERT, PHD
LES SILBERSTEIN, MD